药品目录提交的AMCP格式3.0版
The AMCP format for formulary submissions version 3.0.
出版信息
J Manag Care Pharm. 2010 Jan;16(1 Suppl A):1-30. doi: 10.18553/jmcp.2010.16.S1-A.1.
Abstract
The Academy of Managed Care Pharmacy (AMCP) and the Foundation forManaged Care Pharmacy (FMCP) gratefully acknowledge the contributionsof many individuals who have devoted substantial time, expertise and commitmentin the preparation of the 3rd revision the AMCP Format for FormularySubmissions.
摘要
管理式医疗药学学会（AMCP）和管理式医疗药学基金会（FMCP）衷心感谢众多人士的贡献，他们投入了大量时间、专业知识和精力来准备AMCP药品目录提交格式的第3版修订版。
相似文献
1
The AMCP format for formulary submissions version 3.0.药品目录提交的AMCP格式3.0版
J Manag Care Pharm. 2010 Jan;16(1 Suppl A):1-30. doi: 10.18553/jmcp.2010.16.S1-A.1.
2
The AMCP format for formulary submissions version 2.1.药品目录提交的AMCP格式第2.1版。
J Manag Care Pharm. 2005 Jun;11(5 Suppl B):vi-xvi, 1-29, 1-4.
3
The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report.《管理式医疗药学处方集提交格式：不断发展的标准——管理式医疗药学特别工作组报告基础》
Value Health. 2003 Sep-Oct;6(5):505-21. doi: 10.1046/j.1524-4733.2003.65327.x.
4
AMCP Format dossier requests: manufacturer response and formulary implications for one large health plan.AMCP格式档案请求：一家大型医疗计划的制造商回应及处方集影响
J Manag Care Pharm. 2007 Jan-Feb;13(1):37-43. doi: 10.18553/jmcp.2007.13.1.37.
5
Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers.关于管理式医疗药房档案提交指南的意见：对管理式医疗组织和制药商的一项小型调查结果
J Manag Care Pharm. 2007 May;13(4):360-71. doi: 10.18553/jmcp.2007.13.4.360.
6
Evidence-based and value-based formulary guidelines.基于证据和价值的处方集指南。
Health Aff (Millwood). 2004 Jan-Feb;23(1):124-34. doi: 10.1377/hlthaff.23.1.124.
7
Academy of Managed Care Pharmacy Format: relevance, rigor, regulation, and realism.管理式医疗药学学会格式：相关性、严谨性、规范性与现实性。
Value Health. 2003 Sep-Oct;6(5):501-2. doi: 10.1046/j.1524-4733.2003.65001.x.
8
The case for a value-based formulary: striving for total lowest net cost.基于价值的处方集的理由：追求最低总净成本。
Manag Care Interface. 2007 Apr;20(4):42-7.
9
Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.经济分析在美国管理式医疗药品目录决策中的应用：一家私人支付方的经验。
J Manag Care Pharm. 2006 Nov-Dec;12(9):726-35. doi: 10.18553/jmcp.2006.12.9.726.
10
Evolution of the AMCP Format for Formulary Submissions.医保目录药品申报 AMCP 格式的演变。
J Manag Care Spec Pharm. 2020 Jun;26(6):696-700. doi: 10.18553/jmcp.2020.26.6.696.
引用本文的文献
1
A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the US.引入 sugammadex 常规逆转美国假设队列中神经肌肉阻滞的临床和预算影响分析。
Adv Ther. 2021 May;38(5):2689-2708. doi: 10.1007/s12325-021-01701-1. Epub 2021 Apr 19.
2
An Elective Course for Student Pharmacists on Pharmaceutical Industry Practice.学生药剂师选修课程：制药业实践。
Am J Pharm Educ. 2019 Oct;83(8):7037. doi: 10.5688/ajpe7037.
3
Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea.与韩国单纯宫颈癌筛查相比，在宫颈癌筛查中增加两剂人乳头瘤病毒疫苗接种计划的成本效益分析
Asian Pac J Cancer Prev. 2019 Feb 26;20(2):425-435. doi: 10.31557/APJCP.2019.20.2.425.
4
Evaluating the Cost-Effectiveness of Proportional-Assist Ventilation Plus vs. Pressure Support Ventilation in the Intensive Care Unit in Two Countries.评估两国重症监护病房中比例辅助通气联合与压力支持通气的成本效益
Front Public Health. 2018 Jun 6;6:168. doi: 10.3389/fpubh.2018.00168. eCollection 2018.
5
Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.用于治疗杂合子家族性高胆固醇血症或有临床动脉粥样硬化性心血管疾病的成年患者的 PCSK9 抑制剂的预算影响分析。
Pharmacoeconomics. 2018 Jan;36(1):115-126. doi: 10.1007/s40273-017-0590-5.
6
Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States.基于美国国家监测数据得出的病原体分布情况，头孢洛扎/他唑巴坦联合甲硝唑与哌拉西林/他唑巴坦作为复杂性腹腔内感染初始经验性治疗的成本效益分析
Antimicrob Resist Infect Control. 2017 Oct 27;6:107. doi: 10.1186/s13756-017-0264-2. eCollection 2017.
7
The AMCP Format for Formulary Submissions: Welcome to Version 4.0.《处方集提交的 AMCP 格式：欢迎使用第 4.0 版》。
J Manag Care Spec Pharm. 2016 May;22(5):444-6. doi: 10.18553/jmcp.2016.16071. Epub 2016 Apr 21.
8
Using Certification to Promote Uptake of Real-World Evidence by Payers.利用认证促进支付方采用真实世界证据
J Manag Care Spec Pharm. 2016 Mar;22(3):191-6. doi: 10.18553/jmcp.2016.22.3.191.
9
FDAMA Section 114: Why the Renewed Interest?FDAMA 第 114 节：为何重新引起关注？
J Manag Care Spec Pharm. 2015 May;21(5):368-74. doi: 10.18553/jmcp.2015.21.5.368.
10
Design, implementation, and first-year outcomes of a value-based drug formulary.基于价值的药品处方集的设计、实施和第一年结果。
J Manag Care Spec Pharm. 2015 Apr;21(4):269-75. doi: 10.18553/jmcp.2015.21.4.269.
Zotero 插件